A Phase III, Multicenter, Randomized, Double blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

Condition studied

Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

Investigational medicinal product(s)

Eligibility

Primary endpoint

Change from baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)

Endpoint detail

Change from baseline through Week 72 in ▪ Alzheimer’s Disease Assessment Scale-Cognition 13 (ADAS-Cog-13), Change from baseline through Week 72 in ▪ Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) total score and instrumental score, Change from baseline through Week 72 in ▪ integrated Alzheimer’s Disease Rating Scale (iADRS), Change from baseline through Week 72 in ▪ MMSE, Time to increase in CDR-GS, Nature, frequency, severity of adverse events (AEs) and serious adverse events (SAEs), Change from baseline in clinical laboratory assessments and vital signs, physical examinations (including neurological systems), electrocardiograms (ECGs), and Columbia-Suicide Severity Rating Scale (C-SSRS), Nature, frequency, severity, and timing of amyloid-related imaging abnormalities edema/effusion (ARIA-E) and amyloid-related imaging abnormalities-hemosiderin Deposition (ARIA-H) MRI findings, Nature, frequency, severity, and timing of infusion-related reactions (IRRs), Incidence, onset and titer of anti-drug antibodies (ADAs) to trontinemab during the study relative to the prevalence of ADAs at baseline., Change from baseline through Week 72 in brain amyloid load, as measured by amyloid positron emission tomography (PET) scan, Change from baseline to Week 72 in brain tau load, as measured by tau amyloid PET scan in a subset of participants, Change from baseline through Week 72 in cerebrospinal fluid (CSF) biomarkers of disease phosphorylated tau 181 (p-tau181), Neurogranin, amyloid-beta 42 (Aβ42), Aβ42/40 in a subset of participants, Change from baseline through Week 72 in blood biomarkers p-tau217, glial fibrillar acidic protein (GFAP), Aβ42, Aβ42/40